10/26/2025

Janusmed kön och genus

Janusmed kön och genus – LENVIMA

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Lenvatinib

Lenvatinib

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. LeClair K, Bell KJL, Furuya-Kanamori L, Doi SA, Francis DO, Davies L. Evaluation of Gender Inequity in Thyroid Cancer Diagnosis: Differences by Sex in US Thyroid Cancer Incidence Compared With a Meta-analysis of Subclinical Thyroid Cancer Rates at Autopsy. JAMA Intern Med. 2021;181(10):1351-1358.

  2. Liao CY, Lee CY, Wei CY, Chao Y, Huang YH, Hou MC et al. Differential prognoses among male and female patients with hepatocellular carcinoma. J Chin Med Assoc. 2022;85(5):554-565.

  3. Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol. 2010;6(11):1771-9.

  4. Pang C, Li JM, Wang Z, Luo YC, Cheng ZG, Han ZY et al. Age-Dependent Female Survival Advantage in Hepatocellular Carcinoma: A Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2024;22(2):305-314.

  5. Assessment report - Lenvima (lenvatinib). European Medicines Agency (EMA) [www]. [updated 2015-06-25, cited 2025-09-12].

  6. Gupta A, Jarzab B, Capdevila J, Shumaker R, Hussein Z. Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. Br J Clin Pharmacol. 2016;81(6):1124-33.

  7. Hu Y, Chen R, Ye Z, Wei F, Lin K, Liu J et al. Population Pharmacokinetic Modeling of Lenvatinib in Chinese Patients With Advanced Hepatocellular Carcinoma Using Real-World Data. J Clin Pharmacol. 2022;62(12):1507-1517.

  8. Puliani G, Bianchini M, Giani C, Valerio L, Nervo A, Sapuppo G et al. Gender impact on safety and efficacy in lenvatinib treated patients with radioiodine-refractory differentiated thyroid cancer (GISEL study). Eur Thyroid J. 2025;14(2):.

  9. Lenvima (lenvatinib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-04-22, cited 20205-09-12]

  10. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]

  1. LeClair K, Bell KJL, Furuya-Kanamori L, Doi SA, Francis DO, Davies L. Evaluation of Gender Inequity in Thyroid Cancer Diagnosis: Differences by Sex in US Thyroid Cancer Incidence Compared With a Meta-analysis of Subclinical Thyroid Cancer Rates at Autopsy. JAMA Intern Med. 2021;181(10):1351-1358.
  2. Liao CY, Lee CY, Wei CY, Chao Y, Huang YH, Hou MC et al. Differential prognoses among male and female patients with hepatocellular carcinoma. J Chin Med Assoc. 2022;85(5):554-565.
  3. Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol. 2010;6(11):1771-9.
  4. Pang C, Li JM, Wang Z, Luo YC, Cheng ZG, Han ZY et al. Age-Dependent Female Survival Advantage in Hepatocellular Carcinoma: A Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2024;22(2):305-314.
  5. Assessment report - Lenvima (lenvatinib). European Medicines Agency (EMA) [www]. [updated 2015-06-25, cited 2025-09-12].
  6. Gupta A, Jarzab B, Capdevila J, Shumaker R, Hussein Z. Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. Br J Clin Pharmacol. 2016;81(6):1124-33.
  7. Hu Y, Chen R, Ye Z, Wei F, Lin K, Liu J et al. Population Pharmacokinetic Modeling of Lenvatinib in Chinese Patients With Advanced Hepatocellular Carcinoma Using Real-World Data. J Clin Pharmacol. 2022;62(12):1507-1517.
  8. Puliani G, Bianchini M, Giani C, Valerio L, Nervo A, Sapuppo G et al. Gender impact on safety and efficacy in lenvatinib treated patients with radioiodine-refractory differentiated thyroid cancer (GISEL study). Eur Thyroid J. 2025;14(2):.
  9. Lenvima (lenvatinib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-04-22, cited 20205-09-12]
  10. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]